Literature DB >> 33640365

Incidence and Mortality Trends of Atrial Fibrillation/Atrial Flutter in the United States 1990 to 2017.

Augustin J DeLago1, Mohammed Essa1, Alireza Ghajar1, Matthew Hammond-Haley2, Arshi Parvez1, Isaiah Nawaz3, Joseph Shalhoub4, Dominic C Marshall5, Saman Nazarian6, Hugh Calkins7, Justin D Salciccioli1, Binu Philips8.   

Abstract

Atrial fibrillation (AF) and flutter (AFL) are the most common clinically significant arrhythmias in older adults with an increasing disease burden due to an aging population. However, up-to-date trends in disease burden and regional variation remain unknown. In an observational study utilizing the Global Burden of Disease (GBD) database, age-standardized mortality and incidence rates for AF overall and for each state in the United States (US) from 1990 to 2017 were determined. All analyses were stratified by gender. The relative change in age-standardized incidence rate (ASIR) and age-standardized death rate (ASDR) over the observation period were determined. Trends were analyzed using Joinpoint regression analysis. The mean ASIR per 100,000 population for men was 92 (+/-8) and for women was 62 (+/-5) in the US in 2017. The mean ASDR per 100,000 population for men was 5.8 (+/-0.3) and for women was 4.4 (+/-0.4). There were progressive increases in ASIR and ASDR in all but 1 state. The states with the greatest percentage change in incidence were New Hampshire (+13.5%) and Idaho (+16.0%) for men and women, respectively. The greatest change regarding mortality was seen in Mississippi (+26.3%) for men and Oregon (+53.8%) for women. In conclusion these findings provide updated evidence of increasing AF and/or AFL incidence and mortality on a national and regional level in the US, with women experiencing greater increases in incidence and mortality rates. This study demonstrates that the public health burden related to AF in the United States is progressively worsening but disproportionately across states and among women.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Year:  2021        PMID: 33640365     DOI: 10.1016/j.amjcard.2021.02.014

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Moricizine prevents atrial fibrillation by late sodium current inhibition in atrial myocytes.

Authors:  Tian Zou; Qingxing Chen; Chaofeng Chen; Guijian Liu; Yunlong Ling; Yang Pang; Ye Xu; Kuan Cheng; Wenqing Zhu; Ru-Xing Wang; Ling-Ling Qian; Junbo Ge
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

2.  Pulmonary artery pressure is associated with mid-term major adverse cardiovascular events and postprocedure pericardial effusion in atrial fibrillation patients undergoing left atrial appendage occlusion.

Authors:  Tian Zou; Qingxing Chen; Lei Zhang; Chaofeng Chen; Yunlong Ling; Guijian Liu; Sunying Wang; Yang Pang; Ye Xu; Kuan Cheng; Daxin Zhou; Wenqing Zhu; Junbo Ge
Journal:  Ann Transl Med       Date:  2021-08

Review 3.  The Cardiovascular Manifestations of COVID-19.

Authors:  David W Louis; Marwan Saad; Shilpa Vijayakumar; Suleman Ilyas; Aravind Kokkirala; Herbert D Aronow
Journal:  Cardiol Clin       Date:  2022-03-23       Impact factor: 2.410

4.  Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy.

Authors:  Mette Søgaard; Flemming Skjøth; Peter B Nielsen; Jesper Smit; Michael Dalager-Pedersen; Torben B Larsen; Gregory Y H Lip
Journal:  JAMA Netw Open       Date:  2022-05-02

5.  Preadmission Oral Anticoagulation for Atrial Fibrillation/Flutter and Death or Thrombotic Events During COVID-19 Admission.

Authors:  David W Louis; Kevin F Kennedy; Marwan Saad; Greg Salber; Hafiz Imran; Tyler Wark; Cullen Soares; Dhairyasheel Ghosalkar; Rasan Cherala; Athena Poppas; J Dawn Abbott; Herbert D Aronow
Journal:  Am J Cardiol       Date:  2022-08-13       Impact factor: 3.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.